PML tumour suppression and beyond: Therapeutic implications
Cristina Gamell, Piotr Jan Paul, Ygal Haupt, Sue Haupt
FEBS LETTERS | WILEY | Published : 2014
Recognition of the tumour suppressive capacity of the Promyelocytic Leukemia protein (PML) has emerged beyond its identification through APL, to a broad spectrum of tumors. This ability has chiefly been linked to its role as a core component of dynamic structures termed PML Nuclear Bodies (PML-NBs). In response to a variety of stresses, key factors and their molecular modifiers are recruited to PML-NBs, where activating modifications are facilitated, leading to a cellular stress response. PML was also found to perform anti-tumourigenic functions through cytoplasmic activities. Surprisingly, important recent research defined growth promoting capabilities of PML, which significantly challenges..View full abstract
Related Projects (4)
Awarded by NHMRC
Awarded by NHMRC Fellowship
We apologize to those authors whose work was not directly cited, but rather cited thought reviews, due to space limitations. This work was supported by NHMRC project Grants (1026990, 1026988, 1049179, 1063389) and NHMRC Fellowship to Y.H. (9628426), by the VESKI award, and by the CASS Foundation.